Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Human SYT6 ELISA Kit (AC2582)
Cat.#: ASET-1171
Specifications
Description Human SYT6 ELISA Kit, a 90-minute assay kit, allows for the in vitro quantitative determination of human SYT6 concentrations in serum, plasma, and other biological fluids. Size 96T Sample Type Serum, plasma or other biological fluids. Reactivity Human Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 8.47 ng/L Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 200-3200 ng/L Assay Time ~90 min Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1207 Human ALDH1A1 ELISA Kit (AC2618) Quantitative inquiry ASET-1035 Mouse Adiponectin ELISA Kit (AC2446) Quantitative inquiry ASET-1549 Human MAP1A ELISA Kit (AC2960) Quantitative inquiry ASET-2224 Human Apelin ELISA Kit (AC3635) Quantitative inquiry ASET-1997 Human Stathmin 1 ELISA Kit (AC3408) Quantitative inquiry ASET-2047 Mouse CaSR ELISA Kit (AC3458) Quantitative inquiry ASET-1133 Human Neuroglobin ELISA Kit (AC2544) Quantitative inquiry ASET-1170 Human LMOD1 ELISA Kit (AC2581) Quantitative inquiry ASET-1224 Human HIP1 ELISA Kit (AC2635) Quantitative inquiry ASET-2063 Mouse ABCG1 ELISA Kit (AC3474) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket